Novartis licenses BoomRay radioligand therapy in deal worth up to $900m
Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.
BoomRay is eligible for upfront, development, regulatory and sales milestone payments as well as royalties, while Novartis gains global development and commercialisation rights to the radiopharmaceutical asset.
The agreement adds another early-stage radioligand programme to Novartis' oncology pipeline and highlights continued investment in targeted nuclear medicine.
Field | Content |
Alert Type | Deal |
Companies | Novartis; BoomRay Pharma |
Deal Type | Exclusive global licensing agreement |
Asset or Company | Undisclosed preclinical radioligand therapy |
Therapy Area(s) | Oncology; nuclear medicine |
Technology or Modality | Radioligand therapy |
Development Stage | Preclinical |
Deal Value | Up to US$900 million including upfront, development, regulatory and sales milestone payments, plus royalties |
Geography | Worldwide |
What Happened | Novartis secured exclusive worldwide rights to a preclinical radioligand therapy from BoomRay Pharma. |
Why It Matters | The transaction adds another radiopharmaceutical programme to Novartis' oncology portfolio and reflects continued strategic investment in targeted radioligand therapy. |
Supporting Context | BoomRay is eligible for milestone-based payments across development, regulatory and commercial stages as well as royalties on future sales. |
Strategic Rationale | Novartis expands its radioligand pipeline while BoomRay gains the resources and global development capabilities of a major pharmaceutical partner. |
Potential Impact | Successful development could add another targeted radiopharmaceutical treatment to the oncology market. |
Key Takeaway | Novartis has licensed a BoomRay radioligand therapy globally in a deal worth up to US$900 million. |
What to Watch | Disclosure of the target, progression into clinical development and achievement of early development milestones. |
Primary Source | BoomRay Pharma |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti